Anbio Biotechnology Class A Ordinary Shares (NNNN) - Net Assets
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has net assets worth $30.16 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.24 Million) and total liabilities ($87.84K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Anbio Biotechnology Class A Ordinary Sha to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $30.16 Million |
| % of Total Assets | 99.71% |
| Annual Growth Rate | 85.7% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 156.96 |
Anbio Biotechnology Class A Ordinary Shares - Net Assets Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See NNNN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual net assets of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. For live valuation and market cap data, see NNNN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $30.16 Million | +75.41% |
| 2024-12-31 | $17.19 Million | +16.01% |
| 2023-12-31 | $14.82 Million | +18.11% |
| 2022-12-31 | $12.55 Million | +394.79% |
| 2021-12-31 | $2.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anbio Biotechnology Class A Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 829.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $23.58 Million | 78.19% |
| Common Stock | $14.39K | 0.05% |
| Other Components | $6.56 Million | 21.77% |
| Total Equity | $30.16 Million | 100.00% |
Anbio Biotechnology Class A Ordinary Shares Competitors by Market Cap
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Haining China Leather Market Co Ltd
SHE:002344
|
$696.32 Million |
|
Quanta Storage
TWO:6188
|
$696.32 Million |
|
Manitou BF S.A.
PA:MTU
|
$696.47 Million |
|
Admie Holding S.A
AT:ADMIE
|
$696.51 Million |
|
Qt Group Oyj
HE:QTCOM
|
$695.82 Million |
|
Shanghai Xinhua Media Co Ltd
SHG:600825
|
$695.69 Million |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
$695.53 Million |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
$695.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anbio Biotechnology Class A Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,191,550 to 30,155,023, a change of 12,963,473 (75.4%).
- Net income of 7,226,807 contributed positively to equity growth.
- New share issuances of 7,230,000 increased equity.
- Other factors decreased equity by 1,493,334.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.23 Million | +23.97% |
| Share Issuances | $7.23 Million | +23.98% |
| Other Changes | $-1.49 Million | -4.95% |
| Total Change | $- | 75.41% |
Book Value vs Market Value Analysis
This analysis compares Anbio Biotechnology Class A Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 625.44x to 23.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.03 | $15.86 | x |
| 2022-12-31 | $0.09 | $15.86 | x |
| 2023-12-31 | $0.08 | $15.86 | x |
| 2024-12-31 | $0.41 | $15.86 | x |
| 2025-12-31 | $0.69 | $15.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anbio Biotechnology Class A Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.97%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 74.06%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.00x
- Recent ROE (23.97%) is below the historical average (46.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 100.00% | 57.26% | 0.90x | 1.94x | $2.28 Million |
| 2022 | 79.79% | 42.52% | 1.69x | 1.11x | $8.76 Million |
| 2023 | 15.21% | 33.58% | 0.42x | 1.07x | $771.84K |
| 2024 | 13.80% | 28.99% | 0.43x | 1.10x | $653.69K |
| 2025 | 23.97% | 74.06% | 0.32x | 1.00x | $4.21 Million |
Industry Comparison
This section compares Anbio Biotechnology Class A Ordinary Shares's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,252,702,307
- Average return on equity (ROE) among peers: -94.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $30.16 Million | 100.00% | 0.00x | $696.11 Million |
| Akoya Biosciences Inc (AKYA) | $7.59 Million | -728.97% | 15.46x | $64.44 Million |
| Align Technology Inc (ALGN) | $-84.67 Million | 0.00% | 0.00x | $12.09 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $447.90 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.37 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $924.75 Million |
| Avantor Inc (AVTR) | $4.86 Billion | 14.14% | 1.77x | $5.44 Billion |
| Azenta Inc (AZTA) | $121.80 Million | -15.11% | 0.16x | $1.05 Billion |
| Baxter International Inc (BAX) | $4.09 Billion | 0.98% | 1.08x | $9.94 Billion |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more